Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: The evidence of its therapeutic value

Core Evidence

Volumn 2, Issue 2, 2007, Pages 121-129

  Ardeshna, Kirit M ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Follicular lymphoma; Maintenance; Refractory; Relapsed; Rituximab

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; FLUDARABINE; GLUCOCORTICOID; MITOXANTRONE; PARACETAMOL; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG COST; EAR INFECTION; ECONOMIC ASPECT; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NOSE INFECTION; PHARYNGITIS; QUALITY OF LIFE; RELAPSE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 38049014356     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Ardeshna KM, Smith P. Norton A, et al; British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516-522.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Praiect. J Clin Oncol. 1998;16:2780-2795.
3. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
4. Berinstein NL. Principles of maintenance therapy. Leuk Res. 2006;30 (Suppl. 1):S3-S10.
5. Cancer Research UK. UK cancer incidence statistics. Available at: httD://info.cancerresearchuk.org/cancerstats/incidence/?a=5441 (accessed June 2007).
6. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
7. Colombat P, Brousse N, Morschhauser, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma: survival analyses with extended follow-up of 7 years. Blood. 2006;108. Abstract 486.
8. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol. 2000;18:3135-3143.
9. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447-8452.
10. Forstpointner R, Unterhalt M, Dreyling M, et al; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003-4008.
11. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416-4423.
12. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005;23:1096-1102.
13. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267.
14. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab; maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088-1095.
15. Hainsworth JD, Meng C, Spigel DR, Raefsky EL, Barton JH, Greco FA. Long-term followup of patients with follicular lymphoma (FL) treated with two years of maintenance rituximab: response to rituximab retreatment at progression. Blood. 2006;108. Abstract 4723.
16. Herald M, Pasold R, Srock S, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma and mantle-cell-lymphoma. Blood. 2004;104. Abstract 584.
17. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
18. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood. 2005;106. Abstract 349.
19. Leppä S, Linna M, Nyman H, Taimela E. Cost-effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL). Blood. 2006;108. Abstract 3337.
20. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
21. Maturi B, Mikhael JR, Dunlop WCN, Tilden DT, Wong L. Maintenance therapy with rituximab for follicular lymphoma is cost-effective - a Canadian perspective. Blood. 2006;108. Abstract 343.
22. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
23. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
24. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23:2215-2223.
25. Salles GA, Foussard C, Nicolas M, et al. Rituximab added to alfalFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: to first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood. 2004;104. Abstract 160.
26. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927.
27. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
28. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL. Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019-5026.
29. van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521-3529.
30. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295-3301.